DalsnaFinance

Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection

Markets PR Newswire By PR Newswire 30 Jul 2026 16:40 1 min read
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection

MUMBAI, India and NAPLES, Fla., July 30, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that following approval from the United States Food and Drug Administration (U.S. FDA) for its...

MUMBAI, India and NAPLES, Fla., July 30, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that following approval from the United States Food and Drug Administration (U.S. FDA) for its...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.